Roivant Sciences (ROIV) Cash from Operations (2020 - 2026)
Roivant Sciences' (ROIV) quarterly Cash from Operations came in at 586531000.0 in Q4 2025, up 12.05% YoY from 523458044.28 in Q4 2024, and down 215.91% on a QoQ basis from 185664000.0 in Q3 2025.
Roivant Sciences (ROIV) Cash from Operations (2020 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 6 years of Cash from Operations data on file, last reported at 586531000.0 in Q4 2025.
- Quarterly Cash from Operations rose 12.05% year-over-year to 586531000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 1643464000.0 (up 7.84% YoY) and the FY2026 annual result came in at 750349000.0, up 10.61% from the prior year.
- Cash from Operations retreated to 586531000.0 in Q4 2025, from 185664000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 120596000.0 in Q3 2021 to a low of 666886000.0 in Q4 2024.
- A 5-year average of 340287466.67 and a median of 249932000.0 in 2023 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2021 — Cash from Operations plunged 187.71% — and 2025, when it jumped 30.41%.
- Tracing ROIV's Cash from Operations over 5 years: stood at 530260000.0 in 2021, then declined by 25.28% to 664305000.0 in 2022, then gained by 1.13% to 656811000.0 in 2023, then declined by 1.53% to 666886000.0 in 2024, then rose by 12.05% to 586531000.0 in 2025.
- The last three Cash from Operations figures came in at 586531000.0 (Q4 2025), 185664000.0 (Q3 2025), and 204383000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -270.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -270.50 Mn |
| Jun 30, 2026 | -270.50 Mn |
| Dec 31, 2025 | -586.53 Mn |
| Dec 31, 2025 | -586.53 Mn |
| Sep 30, 2025 | -185.66 Mn |
| Sep 30, 2025 | -185.66 Mn |
| Jun 30, 2025 | -204.38 Mn |
| Jun 30, 2025 | -204.38 Mn |
| Dec 31, 2024 | -666.89 Mn |
| Dec 31, 2024 | -666.89 Mn |
| Sep 30, 2024 | -266.81 Mn |
| Sep 30, 2024 | -266.81 Mn |
| Jun 30, 2024 | -192.83 Mn |
| Jun 30, 2024 | -192.83 Mn |
| Dec 31, 2023 | -656.81 Mn |
| Dec 31, 2023 | -656.81 Mn |
| Sep 30, 2023 | -196.43 Mn |
| Sep 30, 2023 | -196.43 Mn |
| Jun 30, 2023 | -249.93 Mn |
| Jun 30, 2023 | -249.93 Mn |